(VIANEWS) – The NASDAQ opens in less than five hours and Xenetic Biosciences‘s pre-market value is already 4.53% down.

Xenetic Biosciences’s last close was $0.55, 73.56% under its 52-week high of $2.08.

The last session, NASDAQ ended with Xenetic Biosciences (XBIO) jumping 3.77% to $0.55. NASDAQ jumped 3.34% to $11,176.41, after two successive sessions in a row of gains, on what was a very up trend trading session.

Why is Xenetic Biosciences Stock Going up?

Xenetic Biosciences is a biopharmaceutical company that focuses on the development of personalized CAR T platforms. They have developed a pipeline of therapies for cancer that target the neutrophil extracellular trap, which is involved in cancer progression. The company was founded in 2011 and is headquartered in Framingham, Massachusetts.

Investors must remember that Xenetic is still in its early stages, and there are risks. A competitor could come out with a similar product, which will drive prices down and reduce profits. In addition, new government regulations can hurt the biotech industry. However, this is unlikely to happen to Xenetic, which is in a good position for growth. The company is currently operating with extra cash and is able to attract important partners. In addition, the company has a vast market potential.

The company recently received a patent notice for its XCART technology platform. This technology has the potential to treat patients with non-Hodgkin lymphoma. There are few treatments available for this cancer, and Xenetic hopes to fill that gap with its XCART therapy.

Investors should also pay attention to the company’s financial health. Its dividend yield is stable and its management team has a strong track record. In addition, the company’s management is aligned with shareholders’ interests. However, it should be noted that the company’s CEO, Jeff Eisenberg, is a high-paying executive with a hefty compensation. Insider trading may also affect the company’s stock price.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical firm that focuses on advancing XCART, a customized chimeric receptor T cell (CART) platform technology designed to target specific patient-specific tumour neoantigens. It is involved in research and development of oncology therapies and biologic drugs. Cell-based therapies that target the B-cell receptor are developed to treat B-cell lymphomas. By partnering with pharmaceutical and biotech companies, it is also using PolyXen, their proprietary drug delivery platform. Takeda Pharmaceutical Co. Ltd. and Serum Institute of India Limited have signed collaboration agreements. Xenetic Biosciences, Inc. has its headquarters in Framingham, Massachusetts.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.29%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 103.4%, now sitting on 1.36M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 20% and 15.4%, respectively.


Today’s last reported volume for Xenetic Biosciences is 40535 which is 20.99% below its average volume of 50350.

Moving Average

Xenetic Biosciences’s worth is way below its 50-day moving average of $0.78 and way under its 200-day moving average of $0.91.

More news about Xenetic Biosciences (XBIO).


Please enter your comment!
Please enter your name here